|Mr. Zami Aberman||Chairman & Co-Chief Exec. Officer||N/A||N/A||63|
|Mr. Yaky Yanay||Co-Chief Exec. Officer, Pres & Director||N/A||N/A||46|
|Mr. Erez Egozi||CFO, Treasurer & Sec.||N/A||N/A||43|
|Efrat Kaduri||Head of Investor & PR||N/A||N/A||N/A|
|Dr. Hillit Mannor Shachar M.D., M.B.A.||VP of Bus. Devel.||N/A||N/A||N/A|
Pluristem Therapeutics Inc., through its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trials, and manufacture of cell therapeutics products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions. The company develops placenta expanded (PLX) cell therapy products, such as PLX-PAD cells, which has been completed Phase-II clinical trial for the treatment of peripheral and cardiovascular diseases, as well as for the treatment of orthopedic diseases. It also develops PLX-R18 cells for hematopoietic cell transplantation in animals, as well as conducts various in-vivo studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.
Pluristem Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.